SCHEMBL4474623

SCHEMBL4474623

Cc1cc(Br)c(Br)s1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2183304 0.77
SCHEMBL2812953 0.77
SCHEMBL9918972 0.74
SCHEMBL20230333 0.72
SCHEMBL9918971 0.72
SCHEMBL6391854 0.72
SCHEMBL9530427 0.72
SCHEMBL8285092 0.72
SCHEMBL13954139 0.72
SCHEMBL16798610 0.69 GSK3B (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118812499-A Active C site alkylation fluorescent lighting diaryl ethylene organic compound and preparation method and application thereof 中国计量大学 2024-10-22 CN claimed
CN-118812499-A Active C site alkylation fluorescent lighting diaryl ethylene organic compound and preparation method and application thereof 中国计量大学 2024-10-22 CN disclosed
US-20230365544-A1 SMALL MOLECULE INHIBITORS OF CALCIUM CHANNEL ACTIVITY AND USES THEREOF NATIONAL INSTITUTES OF HEALTH 2023-11-16 US disclosed
WO-2023110138-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2023-06-22 WO disclosed
WO-2023275337-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2023-01-05 WO disclosed
WO-2023275336-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2023-01-05 WO disclosed
WO-2023275333-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2023-01-05 WO disclosed
EP-3154973-B1 TRICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL MYERS SQUIBB CO (US) 2018-03-21 EP disclosed
US-9708323-B2 Tricyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands BRISTOL-MYERS SQUIBB COMPANY (US) 2017-07-18 US disclosed
US-20170137425-A1 TRICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL MYERS SQUIBB CO (US) 2017-05-18 US disclosed
EP-1743894-A1 Heterocyclyl-substituted pyrazoline compounds, their preparation and use as medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-17 EP disclosed
WO-2006097293-A2 COMBINATION OF A STEROID SULFATASE INHIBITOR AND AN ASCOMYCIN NOVARTIS AG (CH) 2006-09-21 WO disclosed
US-20040236115-A1 Synthesis of cyclopentadiene derivatives EQUISTAR CHEMICALS, LP 2004-11-25 US disclosed
EP-1387827-A2 SYNTHESIS OF CYCLOPENTADIENE DERIVATIVES Basell Polyolefine GmbH (DE) 2004-02-11 EP disclosed
WO-2002092564-A2 SYNTHESIS OF CYCLOPENTADIENE DERIVATIVES BASELL POLYOLEFINE GMBH (DE) 2002-11-21 WO disclosed
EP-0382106-B1 Process for manufacturing thiophene derivatives HOECHST AG (DE) 1995-06-07 EP disclosed
US-5100520-A Electrochemical Dehalogenation HOECHST AKTIENGESELLSCHAFT (DE) 1992-03-31 US disclosed
US-4992534-A Anticarcinogenic agents with better water solubility, low toxicity, absorption and stability OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1991-02-12 US disclosed
EP-0382106-A2 Process for manufacturing thiophene derivatives HOECHST AKTIENGESELLSCHAFT (DE) 1990-08-16 EP disclosed
EP-0303269-A2 2'-Deoxy-5-fluorouridine derivatives, process for preparing the same and the use thereof OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1989-02-15 EP disclosed